This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shek, L. P.-C.
Right arrow Articles by Lehman, T. J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shek, L. P.-C.
Right arrow Articles by Lehman, T. J. A.
Related Collections
Right arrow Neurology & Psychiatry
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

PEDIATRICS Vol. 103 No. 6 June 1999, pp. 1295-1297

EXPERIENCE AND REASON:
Thalidomide Responsiveness in an Infant With Behçet's Syndrome

Received May 7, 1998; accepted Nov 25, 1998.

Lynette Pei-Chi Shek*, Yoke Sun Lee MDDagger , and Bee Wah Lee*

* Departments of Pediatrics and Dagger  Pathology National University of Singapore Singapore 119074

Thomas Joseph Anjorge Lehman

Division of Pediatric Rheumatology Hospital for Special Surgery, New York 10021

Background.  Behçet's syndrome is a chronic relapsing vasculitis characterized by aphthous stomatitis, genital ulcerations, and uveitis. The disease is a multisystem illness, which may involve the skin, joints, gastrointestinal tract, blood vessels, central nervous system, and other organs.

Case Study.  We report a case of an infant with features of Behçet's syndrome who did not respond to conventional immunosuppression with high-dose corticosteroids and cytotoxic agents. Thalidomide, a potent immune response-modifying drug, was used with marked improvement and resolution of symptoms.

Conclusion.  This finding supports a trial of thalidomide treatment in patients with Behçet's syndrome who are unresponsive to other forms of immunosuppressive therapy or develop undesirable side effects.  Key words:  vasculitis, mouth ulcers, Behçet's syndrome, thalidomide.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
J. A. Kari, V. Shah, and M. J. Dillon
Behcet's disease in UK children: clinical features and treatment including thalidomide
Rheumatology, August 1, 2001; 40(8): 933 - 938.
[Abstract] [Full Text] [PDF]